BACKGROUND: Androgen deprivation with gonadotropin-releasing hormone (GnRH) agonists or orchiectomy is a common but controversial treatment for prostate cancer. Uncertainties remain about its use, particularly with increasing recognition of serious side effects. In animal studies, androgens protect against colonic carcinogenesis, suggesting that androgen deprivation may increase the risk of colorectal cancer. METHODS: We identified 107 859 men in the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database who were diagnosed with prostate cancer in 1993 through 2002, with follow-up available through 2004. The primary outcome was development of colorectal cancer, determined from SEER files on second primary cancers. Cox proportional hazards regression was used to assess the influence of androgen deprivation on the outcome, adjusted for patient and prostate cancer characteristics. All statistical tests were two-sided. RESULTS: Men who had orchiectomies had the highest unadjusted incidence rate of colorectal cancer (6.3 per 1000 person-years; 95% confidence interval [CI] = 5.3 to 7.5), followed by men who had GnRH agonist therapy (4.4 per 1000 person-years; 95% CI = 4.0 to 4.9), and men who had no androgen deprivation (3.7 per 1000 person-years; 95% CI = 3.5 to 3.9). After adjustment for patient and prostate cancer characteristics, there was a statistically significant dose-response effect (P(trend) = .010) with an increasing risk of colorectal cancer associated with increasing duration of androgen deprivation. Compared with the absence of these treatments, there was an increased risk of colorectal cancer associated with use of GnRH agonist therapy for 25 months or longer (hazard ratio [HR] = 1.31, 95% CI = 1.12 to 1.53) or with orchiectomy (HR = 1.37, 95% CI = 1.14 to 1.66). CONCLUSION: Long-term androgen deprivation therapy for prostate cancer is associated with an increased risk of colorectal cancer.
BACKGROUND: Androgen deprivation with gonadotropin-releasing hormone (GnRH) agonists or orchiectomy is a common but controversial treatment for prostate cancer. Uncertainties remain about its use, particularly with increasing recognition of serious side effects. In animal studies, androgens protect against colonic carcinogenesis, suggesting that androgen deprivation may increase the risk of colorectal cancer. METHODS: We identified 107 859 men in the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database who were diagnosed with prostate cancer in 1993 through 2002, with follow-up available through 2004. The primary outcome was development of colorectal cancer, determined from SEER files on second primary cancers. Cox proportional hazards regression was used to assess the influence of androgen deprivation on the outcome, adjusted for patient and prostate cancer characteristics. All statistical tests were two-sided. RESULTS:Men who had orchiectomies had the highest unadjusted incidence rate of colorectal cancer (6.3 per 1000 person-years; 95% confidence interval [CI] = 5.3 to 7.5), followed by men who had GnRH agonist therapy (4.4 per 1000 person-years; 95% CI = 4.0 to 4.9), and men who had no androgen deprivation (3.7 per 1000 person-years; 95% CI = 3.5 to 3.9). After adjustment for patient and prostate cancer characteristics, there was a statistically significant dose-response effect (P(trend) = .010) with an increasing risk of colorectal cancer associated with increasing duration of androgen deprivation. Compared with the absence of these treatments, there was an increased risk of colorectal cancer associated with use of GnRH agonist therapy for 25 months or longer (hazard ratio [HR] = 1.31, 95% CI = 1.12 to 1.53) or with orchiectomy (HR = 1.37, 95% CI = 1.14 to 1.66). CONCLUSION: Long-term androgen deprivation therapy for prostate cancer is associated with an increased risk of colorectal cancer.
Authors: Maureen Sanderson; Ann L Coker; Adriana Perez; Xianglin L Du; Gerson Peltz; Mary K Fadden Journal: Ann Epidemiol Date: 2006-07-12 Impact factor: 3.797
Authors: Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen Journal: J Urol Date: 2007-06 Impact factor: 7.450
Authors: Laurens G Van der Flier; Jacob Sabates-Bellver; Irma Oving; Andrea Haegebarth; Mariagrazia De Palo; Marcello Anti; Marielle E Van Gijn; Saskia Suijkerbuijk; Marc Van de Wetering; Giancarlo Marra; Hans Clevers Journal: Gastroenterology Date: 2006-08-18 Impact factor: 22.682
Authors: Jane A Driver; J Michael Gaziano; Rebecca P Gelber; I-Min Lee; Julie E Buring; Tobias Kurth Journal: Am J Med Date: 2007-03 Impact factor: 4.965
Authors: Yi X Chan; Helman Alfonso; S A Paul Chubb; David J Handelsman; P Gerry Fegan; Graeme J Hankey; Jonathan Golledge; Leon Flicker; Bu B Yeap Journal: Horm Cancer Date: 2017-02-23 Impact factor: 3.869
Authors: Jennifer H Lin; Shumin M Zhang; Kathryn M Rexrode; Joann E Manson; Andrew T Chan; Kana Wu; Shelley S Tworoger; Susan E Hankinson; Charles Fuchs; J Michael Gaziano; Julie E Buring; Edward Giovannucci Journal: Clin Gastroenterol Hepatol Date: 2012-11-28 Impact factor: 11.382
Authors: Wanshui Yang; Edward L Giovannucci; Susan E Hankinson; Andrew T Chan; Yanan Ma; Kana Wu; Charles S Fuchs; I-Min Lee; Howard D Sesso; Jennifer H Lin; Xuehong Zhang Journal: Int J Cancer Date: 2020-01-11 Impact factor: 7.396